Luye Pharma Group Ltd. (HKG: 2186)
Hong Kong
· Delayed Price · Currency is HKD 2.120
0.00 (0.00%)
Jan 3, 2025, 11:59 AM HKT
Luye Pharma Group Revenue
Luye Pharma Group had revenue of 3.07B CNY in the half year ending June 30, 2024, with 7.85% growth. This brings the company's revenue in the last twelve months to 6.31B, up 4.62% year-over-year. In the year 2023, Luye Pharma Group had annual revenue of 6.14B with 2.70% growth.
Revenue (ttm)
6.31B CNY
Revenue Growth
+4.62%
P/S Ratio
1.18
Revenue / Employee
1.20M CNY
Employees
5,270
Market Cap
7.97B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 6.14B | 161.42M | 2.70% |
| Dec 31, 2022 | 5.98B | 781.43M | 15.03% |
| Dec 31, 2021 | 5.20B | -339.42M | -6.13% |
| Dec 31, 2020 | 5.54B | -818.21M | -12.87% |
| Dec 31, 2019 | 6.36B | 1.18B | 22.90% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 26.04B |
| Hansoh Pharmaceutical Group Company | 13.00B |
| JD Health International | 58.84B |
| WuXi Biologics | 18.39B |
| Sinopharm Group | 634.32B |
| Innovent Biologics | 8.01B |
| Sino Biopharmaceutical | 29.86B |
| CSPC Pharmaceutical Group | 33.53B |
Luye Pharma Group News
- 2 months ago - RRJ Buys $150 Million Luye Bonds, First China Deal Since 2019 - BNN Bloomberg